BCL2 and triple-negative breast carcinoma: Doxorubicin-loaded AuNPs (Dox-Bcl2-AuNPs) conjugated with siRNAs targeted the anti-apoptotic gene Bcl-2, significantly reducing its expression in triple-negative breast cancer cells and enhancing clonogenic survival [153].